Anti-PD-1-treated patients who have PD-L1 positive melanomas, have response rates of 50%–60%, and show better survival than PD-L1 negative melanomas, which have response rates of 10%–20% [179,194,409,410,411]. Here, CD274 is linked to melanoma.